Abstract | BACKGROUND: AIM: METHODS: FINDINGS: The median follow-up time was six months in group R and four months in group C. After treatments, the patients in group R showed higher white blood cell (WBC) count and neutrophil count than group C (P = .020, P = .037). CD20-positive B cells in group R remained at a very low level after rituximab treatment and need about 15 months to return to normal level, which was longer than group C (six months). The incidence of infection in these two groups has no significant difference, which was 34.7% (17/30) in group R and 32.5% (13/28) in group C (P = .976). Tuberculosis infections after rituximab treatment were found in three patients for the first time. CONCLUSION:
|
Authors | Honglei Wang, Siyang Yan, Hui Liu, Lijuan Li, Jia Song, Guojin Wang, Huaquan Wang, Yuhong Wu, Zonghong Shao, Rong Fu |
Journal | Journal of clinical laboratory analysis
(J Clin Lab Anal)
Vol. 34
Issue 10
Pg. e23455
(Oct 2020)
ISSN: 1098-2825 [Electronic] United States |
PMID | 32794271
(Publication Type: Journal Article)
|
Copyright | © 2020 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals LLC. |
Chemical References |
- Immunoglobulin A
- Granulocyte Colony-Stimulating Factor
- Rituximab
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anemia, Hemolytic, Autoimmune
(complications, drug therapy)
- Autoimmune Diseases
(complications, drug therapy)
- Female
- Granulocyte Colony-Stimulating Factor
(blood)
- Hematologic Diseases
(complications, drug therapy)
- Humans
- Immunoglobulin A
(blood)
- Infections
(chemically induced, etiology)
- Leukocyte Count
- Male
- Middle Aged
- Purpura, Thrombocytopenic, Idiopathic
(complications, drug therapy)
- Rituximab
(administration & dosage, adverse effects, therapeutic use)
- Thrombocytopenia
(complications, drug therapy)
- Young Adult
|